• Waki Imoto, Hoshi Himura, Kenji Matsuo, Sae Kawata, Ayako Kiritoshi, Ryo Deguchi, Masahiro Miyashita, Shinichiro Kaga, Tomohiro Noda, Katsumi Yamamoto, Koichi Yamada, Kenichiro Uchida, Tetsuro Nishimura, Hiromasa Yamamoto, Yasumitsu Mizobata, and Hiroshi Kakeya.
• Department of Infection Control Science, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan; Department of Infectious Disease Medicine, Osaka City University Hospital, 1-5-7 Asahi-machi, Abeno-ku, Osaka, 545-8586, Japan; Department of Respiratory Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. Electronic address: wakiimoto@gmail.com.
• J. Infect. Chemother. 2021 Jun 1; 27 (6): 911-914.

AbstractCAPA (COVID-19 associated pulmonary aspergillosis) is an important complication of COVID-19. It has been reported that the incidence of CAPA is as high as 19%-33% worldwide. However, its onset has not been reported in Japan. A 72-year-old Japanese man was diagnosed with COVID-19 and was transferred to our hospital due to deterioration of respiratory condition. Treatment with remdesivir, dexamethasone (DEXA), and antibiotics was performed under mechanical ventilation. Although the condition improved temporarily, a new shadow appeared in the lung, and Aspergillus fumigatus was cultured from sputum. The patient was clinically diagnosed with CAPA and treated with voriconazole. However, his progress deteriorated and he died. High-risk COVID-19 patients should be tested for Aspergillus to ensure early diagnosis of CAPA.Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

16 keywords...

hide…